FDA Efforts To Curb Flavored Vapes Said To Draw Supreme Court Review
$MO
$PM
$XXII
Medicinal Chemicals and Botanical Products
Health Care
Medicinal Chemicals and Botanical Products
Health Care
- Bloomberg
- Bloomberg
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/8/2024 | $44.50 → $48.00 | Neutral | Citigroup | |
| 3/5/2024 | Buy → Hold | Argus | ||
| 2/13/2024 | Sell → Hold | Societe Generale | ||
| 1/23/2024 | $105.00 → $86.50 | Buy → Sell | UBS | |
| 1/23/2024 | Sell | UBS | ||
| 11/16/2023 | $95.00 | Neutral | Redburn Atlantic | |
| 6/20/2023 | $109.00 → $117.00 | Neutral → Buy | Citigroup | |
| 4/14/2023 | $114.00 | Buy | Stifel |
8-K - Philip Morris International Inc. (0001413329) (Filer)
25-NSE - Philip Morris International Inc. (0001413329) (Subject)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
Remains on Path to Cash Positive Operations in Q1 2025Commencing Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple CategoriesMocksville, North Carolina--(Newsfile Corp. - November 12, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the third quarter ended September 30, 2024, and provided an update on recent business highlights.Third Quarter 2024 Financial Results (compared to Second Quarter 2024, except as noted)All figures reported below reflect continuing operations, excludin
Philip Morris International affiliate, Swedish Match, earned first-ever FDA authorization for a modified risk marketing claim and now is the first to achieve an FDA renewal PMI affiliates have secured 13 of the 16 modified risk tobacco product (MRTP) authorizations that the FDA has granted, demonstrating the company's commitment to a smoke-free future. The U.S. Food and Drug Administration (FDA) authorized a renewal of a risk modification order submitted by Swedish Match USA, Inc. (Swedish Match), an affiliate of Philip Morris International, Inc. (PMI) (NYSE:PM), for eight General snus products. As part of the authorization, the agency granted use of the modified risk claim to reach
Altria Group, Inc. (NYSE:MO) today reports our 2024 third-quarter and nine-months business results and reaffirms our guidance for 2024 full-year adjusted diluted earnings per share (EPS). "Altria delivered outstanding results in the third quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid operating companies income growth behind the resilience of Marlboro, and in the oral tobacco products segment, our MST brands continued to drive profitability while on! maintained momentum in the marketplace. We also continued to reward shareholders through a growing dividend and share repurchases while making investments in pursuit of our Visio
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
Remains on Path to Cash Positive Operations in Q1 2025Commencing Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple CategoriesMocksville, North Carolina--(Newsfile Corp. - November 12, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the third quarter ended September 30, 2024, and provided an update on recent business highlights.Third Quarter 2024 Financial Results (compared to Second Quarter 2024, except as noted)All figures reported below reflect continuing operations, excludin
Altria Group, Inc. (NYSE:MO) today reports our 2024 third-quarter and nine-months business results and reaffirms our guidance for 2024 full-year adjusted diluted earnings per share (EPS). "Altria delivered outstanding results in the third quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid operating companies income growth behind the resilience of Marlboro, and in the oral tobacco products segment, our MST brands continued to drive profitability while on! maintained momentum in the marketplace. We also continued to reward shareholders through a growing dividend and share repurchases while making investments in pursuit of our Visio
Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 third-quarter and first nine-months results.1 "In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share," said Jacek Olczak, Chief Executive Officer. "This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance." "As a result of our strong year-to-date delivery, we
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second
JP Morgan analyst Jared Dinges maintains Philip Morris Intl (NYSE:PM) with a Overweight and raises the price target from $110 to $125.
As of July 25, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Unilever plc (NYSE:UL) On July 25, Unilever reported quarterly adjusted earnings of $1
Investors with a lot of money to spend have taken a bearish stance on Philip Morris Intl (NYSE:PM). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PM, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 9 uncommon options trades for Philip Morris Intl. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 44%, bearish. Out of all of
Citigroup reiterated coverage of Altria with a rating of Neutral and set a new price target of $48.00 from $44.50 previously
Argus downgraded Philip Morris International from Buy to Hold
Societe Generale upgraded Philip Morris International from Sell to Hold
Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex
Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO
Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what